Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK

British Journal of Ophthalmology

Volumn 100, Issue 2, 2016, Pages 240-245

  Buckle, Miranda ^a   Donachie, Paul H J ^a   Johnston, Robert L ^a  

^a GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CORNEA INJURY; DEMOGRAPHY; ELECTRONIC MEDICAL RECORD; ENDOPHTHALMITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; UNITED KINGDOM; VERY ELDERLY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FOLLOW UP; GREAT BRITAIN; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PEROPERATIVE COMPLICATION; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INTRAOPERATIVE COMPLICATIONS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RANIBIZUMAB; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84956725997     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-306423     Document Type: Article

References (17)

1. NICE. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. 2008. http://www.nice.org.uk/guidance/ta155
2. NICE. Aflibercept solution for injection for treating wet age-related macular degeneration. 2013. https://www.nice.org.uk/guidance/ta294
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-44.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
5. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
6. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-9.
7. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52.
8. Rofagha S, Bhisitkul RB, Boyer DS, et al. Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9.
9. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014;121:1092-101.
10. Gillies MC, Walton R, Simpson JM, et al. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Invest Ophthalmol Vis Sci 2013;54:5754-60.
11. Lee AY, Lee CS, Butt T, et al. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol 2015;99:1045-50.
12. Butt T, Lee A, Lee C, et al. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes. BMJ Open 2015;5:e006535.
13. Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007;125:1249-54.
14. Dawson SR, Mallen CD, Gouldstone MB, et al. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol 2014;14:78.
15. Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol 2011;2011:405724.
16. Rauch R, Weingessel B, Maca SM, et al. Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 2012;32:1260-4.
17. Muether PS, Hoerster R, Hermann MM, et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013;251:453-8.